KRAS and neoplasm: Bolivar and colleagues found a significant association between the presence of plasma ctDNA mutation (CTNNBI, KRAS, PTEN, or PIK3C) and advanced stage, deep myometrial invasion, LVSI, and primary tumour size (91).